Silence Therapeutics plc Share Price
Stocks
SLN
US82686Q1013
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
01:30:00 18/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 12.70 USD | +1.60% |
|
-4.58% | +108.88% |
| Market Cap | 57Cr 76Cr 67Cr 63Cr 106.99Cr 7.32TCr 107.52Cr 750.79Cr 290.31Cr 3.72TCr 287.25Cr 280.86Cr 12TCr | P/E 2026 * |
-23.9x | P/E 2027 * | -19.2x |
|---|---|---|---|---|---|
| Enterprise Value | 44Cr 59Cr 51Cr 48Cr 82Cr 5.62TCr 83Cr 576.31Cr 222.84Cr 2.86TCr 220.5Cr 215.59Cr 9.15TCr | EV / Sales 2026 * |
1,363x | EV / Sales 2027 * | 531x |
| Free-Float |
69.35% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SLN | Delayed | |
CBOE
| SLN | Real-time | |
|
Tradegate
| XRP2 | Real-time | |
|
Deutsche Boerse AG
| XRP2 | Delayed | |
|
Börse Stuttgart
| XRP2 | Delayed | |
|
Boerse Muenchen
| XRP2 | Real-time |
Last Transcript: Silence Therapeutics plc
| 1 day | +1.60% | ||
| 1 week | -4.58% | ||
| Current month | -6.13% | ||
| 1 month | -11.50% | ||
| 3 months | +87.87% | ||
| 6 months | +83.79% | ||
| Current year | +108.88% |
| 1 week | 12.1 |  | 13.28 |
| 1 month | 12.1 | | 15.28 |
| Current year | 4.19 | | 17.58 |
| 1 year | 4.19 | | 17.58 |
| 3 years | 1.97 | | 27.72 |
| 5 years | 1.97 | | 27.72 |
| 10 years | 1.97 | | 35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 01/12/2025 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 01/02/2022 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 21/06/2018 |
Iain Ross
CHM | Chairman | 72 | 01/01/2004 |
Tim McInerney
BRD | Director/Board Member | 65 | 05/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 06/07/26 | Sell | 8,65,112 | 0.6105% | |||
| 02/01/26 | Free | Chief Financial Officer | 3,75,000 | 0.2646% | ||
| 02/01/26 | Free | Director | 90,000 | 0.0635% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.60% | -4.58% | +153.49% | +27.64% | 76Cr | |
| +1.06% | +3.65% | +1.25% | +29.77% | 4.62TCr | |
| +0.23% | +4.72% | +44.32% | +27.27% | 4.43TCr | |
| +0.52% | -3.15% | +349.53% | +520.09% | 4.22TCr | |
| +1.55% | +3.41% | +6.40% | +76.45% | 4.02TCr | |
| +1.75% | -0.28% | +12.42% | +41.11% | 2.98TCr | |
| -0.20% | +5.49% | +23.57% | +119.72% | 1.72TCr | |
| -3.49% | -8.49% | - | - | 1.57TCr | |
| +1.09% | +9.93% | +24.19% | +41.26% | 1.53TCr | |
| -2.45% | +2.41% | -3.16% | -35.16% | 1.31TCr | |
| Average | +0.17% | +1.13% | +68.00% | +94.24% | 2.65TCr | |
| Weighted average by Cap. | +0.47% | +1.71% | +73.29% | +124.79% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3L 4L 4L 4L 6L 4.12Cr 6L 42.27L 16.34L 2.1Cr 16.17L 15.81L 6.71Cr | 8L 10.02L 9L 8L 14.02L 9.6Cr 14.09L 98.39L 38.05L 4.88Cr 37.64L 36.81L 16Cr |
| Net income | -4.21Cr -5.63Cr -4.9Cr -4.64Cr -7.87Cr -538.79Cr -7.91Cr -55Cr -21Cr -273.82Cr -21Cr -21Cr -876.56Cr | -7.1Cr -9.48Cr -8.26Cr -7.82Cr -13Cr -908.02Cr -13Cr -93Cr -36Cr -461.46Cr -36Cr -35Cr -1.48TCr |
| Net Debt | -13Cr -18Cr -15Cr -15Cr -25Cr -1.7TCr -25Cr -174.48Cr -67Cr -864.91Cr -67Cr -65Cr -2.77TCr | -17Cr -23Cr -20Cr -19Cr -33Cr -2.23TCr -33Cr -228.16Cr -88Cr -1.13TCr -87Cr -85Cr -3.62TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/26/17 | $12.70 | +1.60% | 6,90,466 |
| 16/26/16 | $12.50 | +0.32% | 9,83,806 |
| 15/26/15 | $12.46 | -4.59% | 13,83,436 |
| 14/26/14 | $13.06 | +0.31% | 10,95,255 |
| 11/26/11 | $13.02 | -2.18% | 6,85,914 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SLN Stock
Select your edition
All financial news and data tailored to specific country editions
